
    
      Omalizumab is an FDA approved anti-IgE drug used to treat allergic asthma. This study is
      designed to give omalizumab 13 weeks prior to administering rapid build up of specific
      allergy shot, with an overlap of omalizumab and cluster therapy for 3 weeks. The cluster
      therapy will take 4 week to complete with maintenance dosage lasting an additional 6 weeks.
    
  